Generic Product News (November 2020)

Pharmacy Times, November 2020, Volume 88, Issue 11

Generic Product News for November 2020.

PREDNISONE TABLETS, 1 MG

MARKETED BY: Strides Pharma Inc

COMPARE TO: Meticorten

The FDA recently approved Strides Pharma Sciences’s generic prednisone tablets in a dosage strength of 1 mg, used to treat allergic disorders, arthritis, breathing disorders, colitis, lupus, psoriasis, skin conditions, and ulcerative colitis. As a corticosteroid, prednisone tablets decrease the immune system’s response to various diseases to reduce symptoms, such as allergic-type reactions and swelling. Adverse effects can include loss of appetite, nausea, and vomiting.

FOR MORE INFORMATION: strides.com

ICOSAPENT ETHYL, 1 G

MARKETED BY: Hikma Pharmaceuticals USA Inc

COMPARE TO: Vascepa

After its FDA approval in May 2020, the US Court of Appeals for the Federal Circuit upheld a ruling finding that Hikma Pharmaceuticals’ generic icosapent ethyl does not infringe on any Amarin-owned patents, and Hikma is working toward launch. The drug is indicated as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Icosapent ethyl is a type of omega-3 fatty acid, thought to work by decreasing the amount of triglycerides made by the body. Vascepa had a market value of about $1.1 billion in the 12 months ended July 2020, according to IQVIA.

FOR MORE INFORMATION: hikma.com

NIZATIDINE ORAL SOLUTION, 15 MG/ML

MARKETED BY: Amneal Pharmaceuticals

COMPARE TO: Axid

Amneal Pharmaceuticals offers the only oral liquid form of nizatidine available in the United States, indicated for the short-term treatment and maintenance therapy of ulcers and for the treatment of esophagitis and associated heartburn related to gastroesophageal reflux disease. A statement from the company said that its offering is in response to dwindling nazitidine treatment options. It is available as a peppermint-flavored liquid sold in 480-mL bottles.

FOR MORE INFORMATION: amneal.com

AZACITIDINE FOR INJECTION, 100 MG

MARKETED BY: Hikma Pharmaceuticals USA Inc

COMPARE TO: Vidaza

Hikma Pharmaceuticals is introducing azacitidine for injection, available in a dosage strength of 100 mg. The drug is indicated for the treatment of patients with several subtypes of French-American-British myelodysplastic syndrome, including chronic myelomonocytic leukemia, refractory anemia with excess blasts or with excess blasts in transformation, and chronic myelomonocytic leukemia. Azacitidine for injection had a market value of about $82 million in the 12 months ended July 2020, according to data from IQVIA.

FOR MORE INFORMATION: hikma.com